Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia

NCT03726593 is registered in ClinicalTrials.gov with Armed Forces Research Institute of Medical Sciences, Thailand as lead sponsor.

NCT NCT03726593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03726593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia
Lead sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Phase
Phase 4
Overall status
Unknown status
Start date
October 4, 2018
Completion date
December 30, 2022
Enrollment
252 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum malaria (drug resistant)